sciencedaily.com
A new PET scan, the Exendin-PET, is showing remarkable accuracy in identifying benign insulin-producing tumors, or insulinomas, in the pancreas. This research, led by Radboud University Medical Center, addresses a significant gap in current scanning techniques, which often miss these tumors. Insulinomas, while benign, cause troublesome symptoms due to excessive insulin production, leading to low blood sugar levels. Once detected, surgical removal is possible, offering a potential cure for patients.
What’s New?
The Exendin-PET scan detected insulinomas in 95% of adult patients with suspected tumors, a substantial improvement over the 65% detection rate of current PET scans. In a study involving 69 patients, the Exendin-PET scan identified tumors in 13% of cases that were missed by conventional scans, even when combined with CT and MRI. This advancement could streamline diagnostics by reducing the need for multiple imaging techniques. Moreover, all patients who had their tumors located with the Exendin-PET scan underwent successful surgery, with all reporting complete resolution of symptoms.
Why It Matters
Timely and precise detection of insulinomas is crucial for patient outcomes. These tumors, while non-cancerous, lead to serious health issues due to excess insulin production, which causes hypoglycemia. Symptoms like fainting and chronic fatigue can severely affect patients' quality of life. Traditional imaging techniques are not always reliable in identifying these tumors, delaying diagnosis and treatment. Previously, patients sometimes underwent extensive exploratory surgery, risking the removal of significant pancreatic tissue, which could lead to diabetes. The Exendin-PET scan offers a safer, more precise option, eliminating the need for invasive exploratory procedures. Additionally, the scan’s ability to pinpoint insulinomas more accurately could reduce healthcare costs by minimizing reliance on other diagnostic tools.
As this new imaging technology becomes more widely available, it holds the potential to become the standard in clinical practice, improving both diagnostic accuracy and patient care outcomes.